Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Common Equity (2022 - 2025)

Prokidney (PROK) has disclosed Common Equity for 4 consecutive years, with -$1.0 billion as the latest value for Q4 2025.

  • Quarterly Common Equity fell 1.63% to -$1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.0 billion through Dec 2025, down 1.63% year-over-year, with the annual reading at -$1.0 billion for FY2025, 1.63% down from the prior year.
  • Common Equity for Q4 2025 was -$1.0 billion at Prokidney, roughly flat from -$1.0 billion in the prior quarter.
  • The five-year high for Common Equity was $20.2 million in Q1 2022, with the low at -$1.6 billion in Q1 2023.
  • Average Common Equity over 4 years is -$959.3 million, with a median of -$1.0 billion recorded in 2025.
  • The sharpest move saw Common Equity tumbled 20327.23% in 2023, then skyrocketed 31.56% in 2024.
  • Over 4 years, Common Equity stood at -$1.1 billion in 2022, then dropped by 0.62% to -$1.1 billion in 2023, then increased by 9.83% to -$995.0 million in 2024, then fell by 1.63% to -$1.0 billion in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$1.0 billion, -$1.0 billion, and -$1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.